Professional
Added to YB: 2024-02-20
Pitch date: 2023-12-31
GPCR [bullish]
Structure Therapeutics Inc.
+70.38%
current return
Author Info
No bio for this author
Company Info
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States.
Market Cap
$4.8B
Pitch Price
$39.60
Price Target
N/A
Dividend
N/A
EV/EBITDA
-16.69
P/E
-19.18
EV/Sales
N/A
Sector
Pharmaceuticals
Category
growth
Baron Opportunity Fund Portfolio Holding - Structure Therapeutics Inc.
Invested in Structure Therapeutics, developing oral GLP-1 drug for diabetes & obesity. Ozempic/Wegovy dominate but only small % of 32M diabetics & 105M obese use them. Structure a frontrunner for cheaper, accessible oral option in Phase 2, potentially 2nd to market after Lilly's orforglipron this decade.
Read full article (1 min)